p.86 抽出テキスト

CLINICAL STATEMENTS AND GUIDELINES

August 29, 2023 Circulation. 2023;148:e9–e119. DOI: 10.1161/CIR.0000000000001168

Virani et al 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline

15 Mahtta D, Ramsey D, Krittanawong C, et al. Recreational substance use

among patients with premature atherosclerotic cardiovascular disease. Heart. 2021;107:650–656. 16.	 Rimm EB, Williams P, Fosher K, et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999;319:1523–1528. 17.	 NIAAA. What's a “standard drink”? Accessed June 30, 2021. https://www. rethinkingdrinking.niaaa.nih.gov/How-much-is-too-much/what-counts-as-adrink/whats-A-Standard-drink.aspx#:∼:text=-%20Rethinking%20Drinking%20 -%20NIAAA%20What%27s%20a%20%E2%80%9Cstandard,fluid%20 ounces%20or%2014%20grams%20of%20pure%20alcohol. 18.	 Di Castelnuovo A, Rotondo S, Iacoviello L, et al. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation. 2002;105:2836– 2844. 19.	 GBD. 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392:1015–1035. 20.	 Heesch CM, Wilhelm CR, Ristich J, et al. Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans. Heart. 2000;83:688–695. 21.	 Mukherjee D, Lange RA. Management of cocaine-associated non-ST-segment elevation myocardial infarction: is an invasive approach beneficial? J Am Coll Cardiol Intv. 2021;14:637–638. 22.	 Singleton JH, Abner EL, Akpunonu PD, et al. Association of nonacute opioid use and cardiovascular diseases: a scoping review of the literature. J Am Heart Assoc. 2021;10:e021260. 23.	 Monte AA, Shelton SK, Mills E, et al. Acute illness associated with can-

nabis use, by route of exposure: an observational study. Ann Intern Med. 2019;170:531–537. 4.2.5. Sexual Health and Activity 1.	 Lukkarinen H, Lukkarinen O. Sexual satisfaction among patients after coronary bypass surgery or percutaneous transluminal angioplasty: eight-year follow-up. Heart Lung. 2007;36:262–269. 2.	 Dahabreh IJ, Paulus JK. Association of episodic physical and sexual activity with triggering of acute cardiac events: systematic review and meta-analysis. JAMA. 2011;305:1225–1233. 3.	 Muller JE, Mittleman MA, Maclure M, et al. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. JAMA. 1996;275:1405–1409. 4.	 Corona G, Razzoli E, Forti G, et al. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest. 2008;31:799–808. 5.	 Levine GN, Steinke EE, Bakaeen FG, et al. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2012;125:1058–1072. 6.	 Parzeller M, Raschka C, Bratzke H. Sudden cardiovascular death during sexual intercourse--results of a legal medicine autopsy study. Z Kardiol. 1999;88:44–48. 7.	 Foy CG, Newman JC, Berlowitz DR, et al. Blood pressure, sexual activity, and erectile function in hypertensive men: baseline findings from the Systolic Blood Pressure Intervention Trial (SPRINT). J Sex Med. 2019;16:235–247. 8.	 Lapierre H, Chan V, Sohmer B, et al. Minimally invasive coronary artery bypass grafting via a small thoracotomy versus off-pump: a case-matched study. Eur J Cardiothorac Surg. 2011;40:804–810. 9.	 Palm P, Zwisler AO, Svendsen JH, et al. Sexual rehabilitation for cardiac patients with erectile dysfunction: a randomised clinical trial. Heart. 2019;105:775–782. 10.	 Boothby CA, Dada BR, Rabi DM, et al. The effect of cardiac rehabilitation

attendance on sexual activity outcomes in cardiovascular disease patients: a systematic review. Can J Cardiol. 2018;34:1590–1599.

4.2.6 Lipid Management 1.	 LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with

atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435. 2.	 Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670– 1681. 3.	 Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin

therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393:407–415. 4 Randomised trial of cholesterol lowering in 4444 patients with coronary

heart disease:the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389. 5.	 Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–1009. 6.	 Long-Term Intervention with Pravastin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357. 7.	 Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153–162. 8.	 Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23–33. 9.	 Jia X, Ramsey DJ, Rifai MA, et al. Impact of lipid monitoring on treatment intensification of cholesterol lowering therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020;125:874–879. 10.	 Rana JS, Virani SS, Moffet HH, et al. Association of low-density lipoprotein testing after an atherosclerotic cardiovascular event with subsequent statin adherence and intensification. Am J Med. 2021 11.	 Karlson BW, Wiklund O, Palmer MK, et al. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother. 2016;2:212–217. 12.	 Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316:743–753. 13.	 Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329–2345. 14.	 Bohula EA, Morrow DA, Giugliano RP, et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. J Am Coll Cardiol. 2017;69:911–921. 15.	 Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397. 16.	 Bach RG, Cannon CP, Giugliano RP, et al. Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2019;4:846–854. 17.	 Bonaca MP, Gutierrez JA, Cannon C, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018;6:934–943. 18.	 Cannon CP, Khan I, Klimchak AC, et al. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2:959–966. 19.	 Virani SS, Akeroyd JM, Nambi V, et al. Estimation of eligibility for proprotein convertase subtilisin/kexin type 9 inhibitors and associated costs based on the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk): insights from the Department of Veterans Affairs. Circulation. 2017;135:2572–2574. 20.	 Institute for Clinical and Economic Review. Alirocumab for treatment of high cholesterol: effectiveness and value: new evidence update. 2019. Accessed March 1, 2022. https://icer.org/wp-content/uploads/2020/10/ICER_Alirocumab_Final_NEU_021519.pdf. 21.	 Kazi DS, Penko J, Coxson PG, et al. Cost-effectiveness of alirocumab: a just-in-time analysis based on the ODYSSEY outcomes trial. Ann Intern Med. 2019;170:221–229. 22.	 Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722. 23.	 Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097– 2107. 24.	 Talasaz AH, Ho AJ, Bhatty F, et al. Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD. Pharmacotherapy. 2021;41:1009–1023. 25.	 Murphy SA, Pedersen TR, Gaciong ZA, et al. Effect of the PCSK9 inhibitor

evolocumab on total cardiovascular events in patients with cardiovascular

Downloaded from http://ahajournals.org by on October 7, 2026